国泰海通晨报-20260313

Coal Mining Research - The report discusses the historical impact of geopolitical conflicts on coal prices, suggesting that these conflicts may stabilize seasonal price declines and elevate average prices. The ongoing geopolitical tensions, particularly involving the US, Israel, and Iran, have led to higher oil and natural gas prices, which are expected to influence energy prices upward. International coal prices have risen by 20% in response to the surge in natural gas prices, leading to increased expectations for coal demand amid high energy prices [3][4] - Domestic coal supply remains stable, but a reduction in imports due to rising international coal prices may elevate domestic seasonal coal price bottoms, making significant price drops unlikely. The peak supply-demand pressure is expected to end around March-April, with a seasonal increase in electricity coal demand starting in May [3][4] Construction Engineering Research - China Power Construction Corporation (中国电建) is highlighted for its leadership in global clean energy construction, with a significant market share in wind, solar, and hydropower projects. The company has completed over 80% of river planning and more than 65% of large and medium-sized hydropower station construction in China, and it leads over 50% of the global market for large and medium-sized hydropower projects [6][7] - The report notes that the integration of computing and electricity has been included in government reports, which is expected to benefit companies involved in integrated computing and electricity operations. The company has signed contracts worth 210.06 billion yuan for digital transformation projects, including data centers and computing centers [5][7] Biopharmaceutical Research - Rongchang Biopharmaceutical (荣昌生物) is projected to enter a new growth phase starting in 2026, driven by the launch of new indications for its products RC18, RC48, and RC28, which are expected to enter medical insurance coverage. The company anticipates revenue of 32.51 billion yuan in 2025, increasing to 78.32 billion yuan in 2026, and 62.79 billion yuan in 2027 [8][31] - The report emphasizes the potential of RC148, a dual antibody product, which is expected to gain market share through partnerships and new indications, enhancing the company's competitive position in the global oncology market [9][32]